LUMO — Lumos Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $37.41m
- $23.89m
- $2.05m
Annual cashflow statement for Lumos Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43 | -5.66 | -30.4 | -31.1 | -34 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.54 | -4.8 | 2.82 | 2.29 | 1.93 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.59 | -3.62 | -2.31 | 2.1 | 0.965 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.2 | -23 | -29.6 | -26.6 | -31.1 |
| Capital Expenditures | 0 | -0.03 | -0.03 | -0.021 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.077 | 117 | 26 | -11.3 | 10.7 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.077 | 117 | 26 | -11.4 | 10.7 |
| Financing Cash Flow Items | — | — | -0.114 | -0.056 | -0.026 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.059 | 0.075 | -0.192 | -0.821 | -0.576 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -30.2 | 93.7 | -3.87 | -38.8 | -20.9 |